H.R. 9547
Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
Updated Aug 4, 2026, 4:07 AM ET
- Cosponsor Dan Crenshaw (R-TX)
- Cosponsor Seth Moulton (D-MA)
- Cosponsor Jennifer Kiggans (R-VA)
Bipartisan Not enacted
H.R. 9547
Updated Aug 4, 2026, 4:07 AM ET
Bipartisan Not enacted
(a) Findings
Congress finds the following:
(1) Post-traumatic stress disorder often originates during military service and can have persistent effects on force health, medical readiness, retention, family stability, and successful transition from military service to civilian life.
(2) Members of the reserve components and National Guard may also serve in civilian first responder roles, resulting in cumulative trauma exposure that may compound service-connected mental health burdens.
(3) Existing therapies for post-traumatic stress disorder are not effective for all patients, and treatment-resistant cases may be associated with elevated risks of chronic impairment, substance misuse, suicidality, and reduced readiness.
(4) Rigorous, ethical clinical research conducted in accordance with Federal law and force health protection standards is necessary to evaluate emerging treatments for service-connected mental health conditions where existing therapies have proven insufficient.
(5) The State of Arizona has enabled regulatory and administrative support for clinical trials authorized by the Food and Drug Administration evaluating naturally derived, whole-mushroom psilocybin administered within a structured group-therapy setting for the treatment of post-traumatic stress disorder in veterans and first responders.
(6) Private-sector innovators and public-private partnerships play a central role in developing, supplying, and evaluating federally lawful investigational products used in such clinical trials.
(7) Clinical data from the randomized controlled Phase I Passage Trial and the Phase II Fortitude Trial sponsored by the State of Arizona may provide relevant information regarding safety, dosing, adverse events, feasibility, and operational considerations for future research involving veterans, servicemembers, and transitioning servicemembers.
(8) Careful review by the Department of Defense of safety, dosing, feasibility, and continuity-of-care considerations associated with emerging investigational therapies is appropriate to inform future force health protection policy, medical readiness planning, suicide prevention efforts, and military-to-civilian transition support.